These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 12581510)

  • 21. In-vitro intra- and inter-inhaler flow rate-dependent dosage emission from a combination of budesonide and eformoterol in a dry powder inhaler.
    Tarsin W; Assi KH; Chrystyn H
    J Aerosol Med; 2004; 17(1):25-32. PubMed ID: 15120010
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Compatibility and aerosol characteristics of formoterol fumarate mixed with other nebulizing solutions.
    Akapo S; Gupta J; Martinez E; McCrea C; Ye L; Roach M
    Ann Pharmacother; 2008 Oct; 42(10):1416-24. PubMed ID: 18780805
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-acting asthma medication, new inhaler approved by FDA.
    Thompson CA
    Am J Health Syst Pharm; 2001 Apr; 58(7):557-8. PubMed ID: 11296600
    [No Abstract]   [Full Text] [Related]  

  • 24. Inhalation devices for long-acting beta2-agonists: efficiency and ease of use of dry powder formoterol inhalers for use by patients with asthma and COPD.
    Molimard M; Till D; Stenglein S; Singh D; Krummen M
    Curr Med Res Opin; 2007 Oct; 23(10):2405-13. PubMed ID: 20350055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized, double-blind, double-dummy, single-dose, crossover trial evaluating the efficacy and safety profiles of two dose levels (12 and 24 microg) of formoterol-HFA (pMDI) vs. those of a dose level (24 microg) of formoterol-DPI (Foradil/Aerolizer) and of placebo (pMDI or Aerolizer) in moderate to severe asthmatic patients.
    Bousquet J; Guenolé E; Duvauchelle T; Vicaut E; Lefrançois G
    Respiration; 2005; 72 Suppl 1():13-9. PubMed ID: 15915008
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinically equivalent bronchodilatation achieved with formoterol delivered via Easyhaler and Aerolizer.
    Dubakiene R; Nargela R; Sakalauskas R; Vahteristo M; Silvasti M; Lähelmä S
    Respiration; 2006; 73(4):441-8. PubMed ID: 16432294
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Short inhalation exposures of the isolated and perfused rat lung to respirable dry particle aerosols; the detailed pharmacokinetics of budesonide, formoterol, and terbutaline.
    Ewing P; Eirefelt SJ; Andersson P; Blomgren A; Ryrfeldt A; Gerde P
    J Aerosol Med Pulm Drug Deliv; 2008 Jun; 21(2):169-80. PubMed ID: 18518793
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and tolerability of Formoterol Turbuhaler in children.
    Berg AV
    Int J Clin Pract; 2004 Jul; 58(7):728. PubMed ID: 15311734
    [No Abstract]   [Full Text] [Related]  

  • 29. [New study of asthma therapy].
    Krankenpfl J; 2005; 43(4-6):114. PubMed ID: 16171060
    [No Abstract]   [Full Text] [Related]  

  • 30. Interfaces to connect the HandiHaler and Aerolizer powder inhalers to a tracheostomy tube.
    Johnson DC
    Respir Care; 2007 Feb; 52(2):166-70. PubMed ID: 17261204
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bronchodilator response to formoterol Turbuhaler in patients with COPD under regular treatment with formoterol Turbuhaler.
    Cazzola M; Matera MG; D'Amato M; Califano C; Sanduzzi A; Vatrella A; D'Amato G
    Pulm Pharmacol Ther; 2003; 16(2):105-9. PubMed ID: 12670779
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and tolerability of formoterol Turbuhaler in children.
    Von Berg A; Papageorgiou Saxoni F; Wille S; Carrillo T; Kattamis C; Helms PJ
    Int J Clin Pract; 2003 Dec; 57(10):852-6. PubMed ID: 14712884
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bronchoprotective and bronchodilator effects of an HFA pMDI vs. a CFC pMDI and a DPI containing formoterol in asthma patients.
    Langley SJ; Houghton CM; Singh SD
    Respiration; 2005; 72 Suppl 1():35-7. PubMed ID: 15915011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of formoterol delivered through the Novolizer, a novel dry powder inhaler (DPI) compared with a standard DPI in patients with moderate to severe asthma.
    Otto-Knapp R; Conrad F; Hösch S; Metzenauer P; Maus J; Noga O; Petzold U; Kunkel G
    Pulm Pharmacol Ther; 2008; 21(1):47-53. PubMed ID: 17475527
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Output and aerosol properties of 5 nebulizer/compressor systems with arformoterol inhalation solution.
    Bauer A; McGlynn P; Bovet LL; Mims PL; Curry LA; Hanrahan JP
    Respir Care; 2009 Oct; 54(10):1342-7. PubMed ID: 19796414
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Formoterol Turbuhaler as reliever medication in patients with acute asthma.
    Rubinfeld AR; Scicchitano R; Hunt A; Thompson PJ; Van Nooten A; Selroos O
    Eur Respir J; 2006 Apr; 27(4):735-41. PubMed ID: 16455838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term safety of nebulized formoterol: results of a twelve-month open-label clinical trial.
    Donohue JF; Hanania NA; Fogarty C; Campbell SC; Rinehart M; Denis-Mize K
    Ther Adv Respir Dis; 2008 Aug; 2(4):199-208. PubMed ID: 19124372
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Drug clinics. Drug of the month. Formoterol (Oxis turbohaler)].
    Scheen AJ
    Rev Med Liege; 1998 Nov; 53(11):715-8. PubMed ID: 9887666
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fluticasone propionate/formoterol fumarate in fixed-dose combination for the treatment of asthma.
    Price D; Hillyer EV
    Expert Rev Respir Med; 2014 Jun; 8(3):275-91. PubMed ID: 24802285
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Budesonide/formoterol via Turbuhaler® versus formoterol via Turbuhaler® in patients with moderate to severe chronic obstructive pulmonary disease: phase III multinational study results.
    Fukuchi Y; Samoro R; Fassakhov R; Taniguchi H; Ekelund J; Carlsson LG; Ichinose M
    Respirology; 2013 Jul; 18(5):866-73. PubMed ID: 23551359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.